InMed Pharmaceuticals Inc. — Director's Dealing 2021

Nov 9, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: InMed Pharmaceuticals Inc. (INM)
CIK: 0001728328
Period of Report: 2021-11-02

Reporting Person: Johnson Shane Aaron (SVP & GM of BayMedica LLC)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4574	Direct
Common Stock	278428	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$1.40	2026-10-17	Common shares (60000)		Direct
Employee Stock Option (Right to Buy)	$1.40	2026-10-17	Common shares (35000)		Direct

Footnotes

F1: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2: Complete vesting shall occur on the one year anniversary of the grant date (October 18, 2022).